A case of ICIs-associated arthritis caused by Toripalimab initially presenting as oedema in both lower limbs.
IF 1.8
4区 医学
Q3 INFECTIOUS DISEASES
引用次数: 0
Abstract
The use of immune checkpoint inhibitors (ICIs) has offered new hope for patients with malignant tumours; however, it is essential to acknowledge their potential toxic side effects. Among these, ICIs-associated arthritis (IA) is not uncommon but non-specific and lacks diagnostic criteria. In this case, a patient with advanced colon cancer developed IA following treatment with Toripalimab. Notably, the condition improved after the administration of steroids, and the tumour remains well-controlled. This case report significantly contributes to enhancing clinicians' understanding of IA.
多利帕利单抗引起的icis相关性关节炎1例，最初表现为双下肢水肿。
免疫检查点抑制剂（ICIs）的使用为恶性肿瘤患者带来了新的希望；然而，必须承认它们潜在的毒副作用。其中，icis相关性关节炎（IA）并不罕见，但非特异性且缺乏诊断标准。在本例中，一位晚期结肠癌患者在托里帕利单抗治疗后发生IA。值得注意的是，服用类固醇后病情有所改善，肿瘤仍得到良好控制。本病例报告有助于提高临床医生对IA的认识。
本文章由计算机程序翻译，如有差异，请以英文原文为准。
求助全文
约1分钟内获得全文
求助全文
来源期刊
Journal of Chemotherapy
医学-药学
CiteScore
3.70
自引率
0.00%
发文量
144
审稿时长
6-12 weeks
期刊介绍：
The Journal of Chemotherapy is an international multidisciplinary journal committed to the rapid publication of high quality, peer-reviewed, original research on all aspects of antimicrobial and antitumor chemotherapy.
The Journal publishes original experimental and clinical research articles, state-of-the-art reviews, brief communications and letters on all aspects of chemotherapy, providing coverage of the pathogenesis, diagnosis, treatment, and control of infection, as well as the use of anticancer and immunomodulating drugs.
Specific areas of focus include, but are not limited to:
· Antibacterial, antiviral, antifungal, antiparasitic, and antiprotozoal agents;
· Anticancer classical and targeted chemotherapeutic agents, biological agents, hormonal drugs, immunomodulatory drugs, cell therapy and gene therapy;
· Pharmacokinetic and pharmacodynamic properties of antimicrobial and anticancer agents;
· The efficacy, safety and toxicology profiles of antimicrobial and anticancer drugs;
· Drug interactions in single or combined applications;
· Drug resistance to antimicrobial and anticancer drugs;
· Research and development of novel antimicrobial and anticancer drugs, including preclinical, translational and clinical research;
· Biomarkers of sensitivity and/or resistance for antimicrobial and anticancer drugs;
· Pharmacogenetics and pharmacogenomics;
· Precision medicine in infectious disease therapy and in cancer therapy;
· Pharmacoeconomics of antimicrobial and anticancer therapies and the implications to patients, health services, and the pharmaceutical industry.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
